03
August
2022


Share on networks

The German company Merck has invested 14.5 million euros in its facilities in Mollet del Vallès (Barcelona). This large investment will meet increased demand for the company’s specific products in its Life Sciences sector, such as the production of some Covid-19 vaccines.

The expansion project is a further demonstration of the Merck Group’s commitment to its operations in Catalonia while reinforcing its commitment to international supply solutions at this site, as production from the new building will be exported around the world.

Miguel Fernández Alcalde, Managing Director of Merck in Spain, said: “In the last 4 years Merck has invested a total of 90 million euros in the Mollet del Vallès site and in the biotechnology plant in Tres Cantos (Madrid). This has had a clear impact on our production and export capacity from Spain. Specifically, around 99% of the production developed at the Mollet del Vallès site is exported to other countries”.

Share on networks

Related news

La inversió immobiliària es duplica a Barcelona i la contractació d’oficines creix un 13%

News

Real estate investment doubles in Barcelona and office leasing grows by 13%

El gegant automobilístic xinès Chery obrirà un centre d’R+D a Cornellà  de Llobregat

News

Chinese automotive giant Chery to open R&D centre in Cornellà de Llobregat

La japonesa Trend Micro, líder mundial en ciberseguretat, tria Barcelona per obrir el seu hub a Europa

News

Japanese cybersecurity leader Trend Micro chooses Barcelona for its European hub

Barcelona Catalonia
Privacy Overview

This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.